A5015344411- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Cytomegalovirus and herpesvirus research
- Childhood Cancer Survivors' Quality of Life
- DNA Repair Mechanisms
- Protein Degradation and Inhibitors
- Advanced biosensing and bioanalysis techniques
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Hemoglobinopathies and Related Disorders
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
Gunma Saiseikai Maebashi Hospital
2013-2022
Hudson Institute
2020
John Wiley & Sons (United States)
2020
University of Split
2016
The University of Queensland
2016
Okayama University Hospital
2014
Anjo Kosei Hospital
2014
Kurashiki Central Hospital
2014
Emory University
2013
Gunma University
2013
The superiority of the pediatric protocol for adolescents with acute lymphoblastic leukemia (ALL) has already been demonstrated, however, its efficacy in young adults remains unclear. ALL202-U was conducted to examine and feasibility a (AYAs) BCR-ABL-negative ALL. Patients aged 15-24 years (n=139) were treated same used B-ALL. primary objective this study assess disease-free survival (DFS) rate secondary aims toxicity, complete remission (CR) overall (OS) rate. CR 94%. 5-year DFS OS rates...
Key Points KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not those CBFB-MYH11. NRAS
This study aimed at determining how cytogenetic risk status affects outcomes for patients with acute myeloid leukemia (AML) after undergoing various types of allogeneic hematopoietic cell transplantation (HCT). Of 7812 eligible analysis, was classified as favorable 1088, intermediate 5025, and poor 1699. Overall, multivariate analysis showed significant intergroup differences in terms relapse survival, the difference between poor- intermediate-risk groups being greater than that favorable-...
Gilteritinib, a novel, highly specific, potent fms ‐like tyrosine kinase 3/ AXL inhibitor, demonstrated antileukemic activity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). In this open‐label phase 1 study ( NCT 02181660), Japanese (aged ≥18 years) R/R AML received once‐daily gilteritinib, escalating from 20 to 300 mg/d. Primary endpoints were safety/tolerability, including the maximum tolerated dose (MTD) and recommended (RD); secondary pharmacokinetics (PK)....
Older recipient and donor age were associated with higher incidences of severe graft-versus-host disease (GVHD) mortality after allogeneic hematopoietic stem cell transplantation from matched sibling donors (MSDs) unrelated donors. Since a lower incidence GVHD is advantageous in cord blood (CBT), using older MSDs could be overcome for patients. We retrospectively analyzed Japanese registration data 2,091 patients acute myeloid leukemia, lymphoblastic leukemia (ALL), myelodysplastic syndrome...
Although the introduction of imatinib dramatically improved outcomes for patients with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph + BCP-ALL), survival benefit has not been assessed in context Ph mixed phenotype MPAL). To clarify this important issue, we studied 42 Ph+ AL) who received intensive chemotherapy and concurrent administration imatinib. Of AL patients, 13 (31%) were categorized as MPAL (positive both myeloid lineage), 27 (64%) BCP-ALL, two...
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were incidence dose-limiting toxicities. Secondary best response remission duration. Other included safety pharmacokinetics. Patients who ineligible for standard induction therapy or relapsed refractory disease received monotherapy as 2-h infusion on days 1 15...
Abstract The standard treatment for adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, ∼40% of patients cannot undergo HSCT their first complete remission (CR1) because chemotherapy-related toxicities or relapse before older age. In this study, we evaluated dasatinib-based 2-step induction the primary end point 3-year event-free survival...
To investigate the clinical significance of granulocytic sarcoma (GS) in adults with acute myeloid leukemia (AML), 434 consecutive patients AML were analyzed retrospectively. Forty-five (10.4%) GS at diagnosis younger (P < 0.001), presented higher white blood cell counts = 0.03) and more likely to conform French-American-British M4 0.001) M5 0.045) classifications than those without GS. In contrast, no significant difference frequency cytogenetic abnormalities was found between non-GS...
Recent advances in allogeneic hematopoietic stem cell transplantation have led to increasing use of this modality older patients who tend been more heavily pretreated and comorbidities. Thus, the evaluation comorbidity is importance precisely assess benefits risks procedure. Researchers from Seattle developed transplantation-specific index (HCT-CI), which was associated with risk mortality several retrospective studies. However, its clinical utility has not extensively documented prospective...
No standard of care for pure red cell aplasia (PRCA) after major ABO-incompatible hematopoietic stem transplantation (HSCT) has been established. We conducted a retrospective cohort study to learn the efficacy and outcome treatment PRCA. One hundred forty-five recipients who showed delayed recovery erythropoiesis survived >100 days without early disease progression were selected from 2846 records in registry database Japan, detailed data 46 collected. Treatment PRCA, such as rapid tapering...
Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed efficacy allo-SCT MPAL. Eighteen were identified from transplant outcome database Kanto Study Group Cell Therapy (KSGCT). We also selected 215 myeloid (AML) lymphoblastic (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate was...